Gene · 8744
Papers3,166
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,166
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Systematic analysis of the prognostic value and immunological function of LTBR in human cancer. | Aging (Albany NY) | 2024 | 38175686 | PubTator, text mining | PubMed |
| Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K/Akt/mTOR pathway in clear cell renal cell carcinoma. | Heliyon | 2024 | 38173514 | PubTator, text mining | PubMed |
| 4-1BB immunotherapy: advances and hurdles. | Exp Mol Med | 2024 | 38172595 | PubTator, text mining | PubMed |
| Identification of basement membrane-related signatures for estimating prognosis, immune infiltration landscape and drug candidates in pancreatic adenocarcinoma. | J Cancer | 2024 | 38169540 | PubTator, text mining | PubMed |
| Path towards mRNA delivery for cancer immunotherapy from bench to bedside. | Theranostics | 2024 | 38164145 | PubTator, text mining | PubMed |
| Red blood cells in biology and translational medicine: natural vehicle inspires new biomedical applications. | Theranostics | 2024 | 38164142 | PubTator, text mining | PubMed |
| Agonist Antibodies for Cancer Immunotherapy: History, Hopes, and Challenges. | Clin Cancer Res | 2024 | 38153346 | PubTator, text mining | PubMed |
| Precocious infant fecal microbiome promotes enterocyte barrier dysfuction, altered neuroendocrine signaling and associates with increased childhood obesity risk. | Gut Microbes | 2024 | 38117587 | PubTator, text mining | PubMed |
| Identification of TFR2 as a novel ferroptosis‑related gene that serves an important role in prognosis and progression of triple‑negative breast cancer. | Oncol Lett | 2024 | 38106522 | PubTator, text mining | PubMed |
| Identification and validation of N7 -methylguanosine-associated gene NCBP1 as prognostic and immune-associated biomarkers in breast cancer patients. | J Cell Mol Med | 2024 | 38071502 | PubTator, text mining | PubMed |
| Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. | Blood Adv | 2024 | 38019014 | PubTator, text mining | PubMed |
| Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells. | Int Immunopharmacol | 2024 | 37995568 | PubTator, text mining | PubMed |
| CDK4/6 inhibitors induce breast cancer senescence with enhanced anti-tumor immunogenic properties compared with DNA-damaging agents. | Mol Oncol | 2024 | 37854019 | PubTator, text mining | PubMed |
| NK cell-based tumor immunotherapy. | Bioact Mater | 2024 | 37601277 | PubTator, text mining | PubMed |
| CLEC11A expression as a prognostic biomarker in correlation to immune cells of gastric cancer. | Biomol Biomed | 2024 | 37597212 | PubTator, text mining | PubMed |
| Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer. | Curr Cancer Drug Targets | 2024 | 37539926 | PubTator, text mining | PubMed |
| Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer. | Environ Toxicol | 2024 | 37310098 | PubTator, text mining | PubMed |
| Single-Cell Atlas of Atherosclerosis Patients by Cytof: Circulatory and Local Immune Disorders. | Aging Dis | 2024 | 37307820 | PubTator, text mining | PubMed |
| Topical drug delivery strategies for enhancing drug effectiveness by skin barriers, drug delivery systems and individualized dosing. | Front Pharmacol | 2023 | 38293666 | PubTator, text mining | PubMed |
| Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity. | Front Immunol | 2023 | 38283365 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8744/papers?page=11